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BARRIERS TO PEDIATRIC BLOOD LEAD SCREENING
Amanda Abramson, Catherine Avener MS, Jillian Brennan, Elizabeth Hill, Britton Keeshan MPH, Jeffrey MacLean MS,
Kelly Mebust, Sanchit Maruti MS, Wendy Davis MD, Austin Sumner MD, MPH and Jan Carney MD, MPH
University of Vermont School of Medicine and Vermont Department of Health

Background

The pernicious effects of lead on the health of
children are well-documented. The severity of many
of these effects directly correlates with increasing
blood lead levels (BLLs). The current
recommendation from the Centers for Disease
Control and Prevention (CDC) and the American
Academy of Pediatrics (AAP) is that BLLs 10 g/dL
are dangerous.1 However, new evidence
demonstrates that there is no safe BLL and that
children with BLLs <10 g/dL exhibit neurological
and social deficits.2 The Vermont Department of
Health (VDH) currently recommends universal blood
lead screening for 12 and 24 month-old children.3 In
2006, 79% of 12 month-old children and 41% of 24
month-old children were screened in Vermont.

Objectives
To identify barriers preventing Vermont
pediatricians from performing blood lead
screening on 24 month-old children.
To identify specific predictors associated with
lower rates of screening using data from a
descriptive population study.

Methods
A web-based survey was distributed to all
currently licensed Vermont primary care
pediatricians to obtain descriptive information
regarding current lead screening practices.
Pediatricians were assigned to a higher, lower or
unknown screening group based on blood lead
screening rates from the Vermont Immunization
Registry and the Childhood Lead Poisoning
Prevention Program Registry.
Univariate and multivariate analyses were used to
assess factors associated with higher versus
lower blood lead screening rates.

TABLE 4: Logistic regression analysis of determinants associated with lower lead screening
in 61 Vermont primary-care pediatricians

TABLE 1: Demographic characteristics of survey respondents
Demographic characteristic
Sex (% male)
Age (%  50 years)
Residency training city size
(%  500,000 people)
Years in practice (%  15)
Practice in Chittenden County
Practice type
Academic practice (%)
Group practice (non-academic) (%)
Solo practice (%)
Proportion of patient
population on Medicaid
1st tercile (0-39%)
2nd tercile (40-53%)
3rd tercile (54-100%)

Higher screening Lower screening
All (n=72)
(n=30*)
(n=31*)
40.3
36.7
38.71
52.8
60
48.39

p-value†
ns (0.87)
ns (0.36)

56.9

60

54.84

ns (0.68)

44.4
37.5

46.7
26.7

41.94
54.84

ns (0.71)
0.025

15.3
73.6
11.1

26.7
60
13.3

9.68
83.87
6.45

ns (0.08)
0.04
ns (0.37)

31.9
31.9
36.2

3.3
43.3
53.3

58.1
29
12.9

Determinants
Crude POR
Sex
Female
Male
1.09
Perceived lead level at which
negative health outcomes begin
10 g/dL
>10 g/dL
3.64
Proportion of patient population
on Medicaid
1st tercile (0-39%)
2nd tercile (40-53%)
3rd tercile (54-100%)

<0.001
¥

*Information on screening rate is unknown for 11 respondents.
†p-values calculated to compare participants who had higher and lower screening rates. Bold type
indicates statistical significance (2 one-tailed alpha, p 0.05).

0.04
0.01

95% CI

0.39 to 3.07

1.26 to 10.47

0.004 to 0.34
0.001 to 0.14

Adjusted POR

Adj. 95% CI

Coefficient¥

Std. Err.

p-value

8.39

~~Referent~~
1.11 to 62.92

2.13

1.03

0.039

43.06

~~Referent~~
4.03 to 460.09

3.76

1.21

0.002

~~Referent~~
0.000 to 0.131
-4.96
0.000 to <0.0001
-7.07

1.49
1.85

0.001
<0.001

0.007
0.001

Coefficients are used to predict Lower vs. Higher individual pediatrician’s practice screening rate. Sex (1 if male); Lead level (1 if >10 g/dL); 2nd Medicaid tercile

(1 if Yes); 3rd Medicaid tercile (1 if Yes). P>0.5 suggests a 24 month year old screening rate <37.5% [Sensitivity=0.90, Specificity=0.83, Positive Predictive Value
(PPV)=0.85, Negative Predictive Value (NPV)=0.89]

TABLE 2: Prevalence Odds Ratios (POR) for Vermont pediatricians as indicators of lower blood screening

All (n=72)

Higher screening (n=30*) Lower screening (n=31*)
N
%
N
%
Prevalence Odds Ratio 95% CI†

Description of Pediatric Practices
N
%
Reported blood lead level at which risk for negative health
36
50
10
33.3
20
64.5
outcomes begins (>10 μg/dL)
61
84.7
28
93.3
24
77.4
Reported routinely screen 12 month olds
Reported routinely screen 24 month olds
37
51.4
20
66.7
12
38.7
60
83.3
25
83.3
26
83.9
Collected blood samples in Office
43
59.7
20
66.7
16
51.6
Collected blood samples at hospital
61
84.7
26
86.7
26
83.9
Collected blood samples at public health/WIC clinic
38
52.9
14
46.7
18
58.1
Reported adequate reimbursement for lead screening
Report that there is sufficient evidence to warrant universal
61
84.7
25
83.3
27
87.1
blood lead screening in VT children
Reported awareness of the VDH's current lead screening
64
88.9
30
100
25
80.7
recommendation
Reported agreement with the current VDH
36
50
21
70
10
32.3
recommendation
*Information on screening rate is unknown for 11 respondents.
†PRs calculated to compare participants who had higher and lower screening rates. Bold type indicates statistical significance (CI excludes the null).
§Variable predicts outcome perfectly.

3.64

1.12-11.99

0.24

0.05-1.29

0.32

0.11-0.90

1.04
0.53
0.8
1.58

0.27-4.03
0.19-1.50
0.19-3.32
0.58-4.35

1.35

0.33-5.60

§

§

0.2

0.07-0.60

TABLE 3: Percent of respondents reporting any influence of eight common
barriers on his/her blood lead screening practices
Higher Screening Lower Screening
Self-reported barriers to lead screening
All (n=72)
p-value†
(% Reporting)
(n=30*)
(n=31*)
Parental opposition
79.2
90
71
ns (0.06)
No exposure/risk on assessment
58.3
66.7
51.6
ns (0.23)
Difficulty obtaining sample
55.6
66.7
41.9
0.05
Patient compliance
49.7
70
51.6
ns (0.14)
Staffing
48.6
63.3
38.7
0.05
Time
47.2
56.7
41.9
ns (0.25)
Cost to physician
41.7
53.3
35.5
ns (0.16)
Cost to patient
37.5
46.7
32.3
ns (0.25)
*Information on screening rate is unknown for 11 respondents.
†p-values calculated to compare participants who had higher and lower screening rates. Bold type indicates
statistical significance (2 one-tailed alpha, p 0.05).

While survey data demonstrate that 50% of
Vermont pediatricians disagreed with the VDH
blood lead screening recommendations, the
majority of respondents (88%) reported using the
VDH as a primary source of information and
guidance when establishing office policy.
Therefore, the VDH has an opportunity to redesign
its physician education to convey the importance of
universal lead screening at 24 months through
emphasis on the significant health risks associated
with BLLs 10g/dL. Multivariate analysis also
indicates that physicians with larger Medicaid
populations have significantly higher screening
rates. We recommend that the VDH further
investigate this association to determine strategies
to increase blood lead screening rates in 24 monthold children.

Limitations
Respondents were assigned to screening groups
based on practice screening rates. Thus, while
pediatricians practicing independently are
accurately represented by these figures, those in
group practice may have been assigned rates that
are not representative of their individual
screening.
“Higher” screening was defined as a rate above
the median (37.5%), thus many individuals in this
group may still be far from achieving ideal
screening practices.

Lessons Learned

While data collection often presents many

Results
 72 out of 98 pediatricians responded (~74%).
 Factors associated with lower lead screening rates
included practicing in Chittenden County, belonging to a
non-academic group practice and having a low selfreported Medicaid population (Table 1).
 52.8% of pediatricians believed that they are not
adequately reimbursed for blood lead screening. The
reported mean cost of screening per patient was $22.30,
while the desired reimbursement amount was $27.30 (the
current Medicaid reimbursement rate is $4.00).4
 Pediatricians were more likely to be in the higher
screening group if they reported that a BLL 10g/dL is
associated with negative health outcomes, reported
agreeing with the VDH lead screening

Conclusions

recommendations, or reported routinely screening all 24
month-old children for blood lead (Table 2).
 The three most-reported barriers to lead screening were
parental opposition, difficulty obtaining samples and no
risk on assessment (Table 3).
 Multivariate analysis indicated that the most significant
determinants of lower versus higher screening rates are
gender of the pediatrician (contributes 9%), perceived
dangerous BLL (contributes 28%) and self-reported
Medicaid population (contributes 63%) (Table 4).
 The top two sources of lead screening information
utilized by pediatricians in this study were the VDH (88%)
and the AAP (69%).

challenges, the use of a web-based survey was an
effective and timely method for gathering
information regarding physician opinion. Data
analysis and subsequent interpretation in light of
public policy proved more difficult than anticipated.
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